RxDoctor Payments Data

Christopher Grenier, MD

Ophthalmology · Baton Rouge, LANPI 1700818135

Payments from drug & device makers

$1,307in general payments, 2019–2025

Across 34 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$699
  • AbbVie$297
  • Glaukos Corporation$113
  • Aerie Pharmaceuticals, Inc.$80
  • NEW World Medical,inc.$55
  • Biotissue Holdings Inc.$52
  • plus $13 from 1 others

What the payments were for

  • Speaking & faculty fees$1008%
  • Food & beverage$1,12886%
  • Education$806%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,307 in reported general payments places this provider in the 40th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$108,852
Medicare patients
420
Services billed
1,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost267$116,986
RhopressaNetarsudil Mesylate112$50,201
RestasisCyclosporine51$49,346
LumiganBimatoprost107$36,787
VyzultaLatanoprostene Bunod52$20,714
CombiganBrimonidine Tartrate/Timolol66$19,782
Cyclosporine27$13,926
Prednisolone Acetate395$13,822
Latanoprost1,054$13,512
Brimonidine Tartrate233$12,141
Gatifloxacin148$9,092
XiidraLifitegrast12$7,826
Cevimeline Hcl34$6,807
IyuzehLatanoprost/Pf23$6,513
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat373$6,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$80$167,187379 claims
AbbVieRestasis, Lumigan, Combigan$297$105,916224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →